How do Digital Therapeutics (DTx) help address the challenges facing healthcare systems?

by Patricia Domínguez, February 11, 2026

Today, healthcare systems worldwide are facing major challenges driven by population ageing and the rising prevalence of chronic diseases. This situation is leading to growing demand for healthcare services and increasing healthcare expenditure. As a result, there is an urgent need to move towards more preventive, personalised, and value-based care models in order to respond effectively and sustainably to the needs of the healthcare sector.

In this context, what role can Digital Therapeutics (DTx) play?

As we know, Digital Therapeutics (DTx) are clinically evaluated software-based interventions designed to prevent, manage, and/or treat diseases and medical conditions. They deliver measurable clinical outcomes and drive meaningful improvements in patient care.

These digital solutions, which can be used either as standalone interventions or in combination with conventional treatments, act as an extension of healthcare professionals, expanding care beyond the clinical setting and enabling data-driven decision-making based on Real-World Data (RWD) generated directly by patients.

In this way, Digital Therapeutics offer significant benefits to patients, healthcare professionals, industry, and healthcare systems as a whole.

For patients, DTx provide access to personalised care and treatments from home, supporting better disease and symptom management, improving treatment adherence, and reducing unnecessary visits to the hospital.

For healthcare professionals, Digital Therapeutics support patient care and clinical decision-making, helping to alleviate care delivery pressures and prioritise patients who require intervention. At the same time, they contribute to improved health outcomes, leading to fewer complications.

For pharmaceutical and medical device companies, DTx enable the generation of Real-World Evidence (RWE) related to their products and help optimise key parameters such as treatment adherence. In addition, they enhance patient experience, increasing satisfaction when used in combination with their therapies.

Finally, Digital Therapeutics contribute to reducing healthcare system costs by improving the efficiency of medical interventions. They also facilitate access to care—particularly valuable in high-demand therapeutic areas—and support the transition towards value-based healthcare models, where patient outcomes take precedence over the volume of interventions delivered.

These benefits are already being demonstrated in therapeutic areas such as Diabetes and Oncology, among many others. In Diabetes, evidence shows that DTx help improve glycaemic control in patients with type 2 diabetes. In Oncology, the use of Digital Therapeutics has been shown to reduce symptoms such as depression and anxiety, while improving patients’ quality of life.

For all these reasons, Digital Therapeutics have the potential to become a key enabler in addressing the global challenges faced by healthcare systems. Their adoption will support the evolution towards more sustainable healthcare systems, with more proactive and personalised care and a clear focus on patient outcomes—ultimately improving both patient experience and quality of life.